Who is sponsoring NCT06318091?

NCT06318091 is sponsored by Mansoura University.

What drugs are being tested in NCT06318091?

Interventions in NCT06318091: platelet poor plasma gel, nanofat.

What condition does NCT06318091 study?

NCT06318091 studies Tear Trough Eyelid Deformity.

Is NCT06318091 still recruiting?

NCT06318091 is currently completed. Last updated 19 March 2024.

Last reviewed 2024-03-19 · How we verify

NCT06318091

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nanofat Versus Platelet Poor Plasma Gel for Infraorbital Rejuvenation

Completed Phase 1 Last updated 19 March 2024

What this trial tests

Phase 1 trial testing platelet poor plasma gel in Tear Trough Eyelid Deformity in 60 participants. Completed in 1 June 2023.

Timeline

1 June 2021

Primary endpoint
1 June 2023

1 June 2023

Quick facts

Lead sponsor	Mansoura University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 June 2021
Primary completion	1 June 2023
Estimated completion	1 June 2023
Sites	1 location across Egypt

Drugs / interventions tested

platelet poor plasma gel
nanofat — full drug profile →

Conditions studied

Tear Trough Eyelid Deformity — all drugs for Tear Trough Eyelid Deformity →

Sponsor

Mansoura University

Who can join

Eligibility, any sex, with Tear Trough Eyelid Deformity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

this study was conducted for evaluation of the clinical efficacy, safety, and potential side effects of platelet poor plasma gel versus nonfat injection in infraorbital rejuvenation

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Mansoura University trials

Trials by the same sponsor.

NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
NCT07534943 — Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Period · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06318091 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mansoura University
Last refreshed: 19 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06318091.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing